TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Bluefish Pharmaceuticals AB (publ)
Closing information (x1000 EUR)
| Closing information | 2024/04 (consolidated) | 2023/04 (consolidated) | 2021/12 (consolidated) |
| Turnover |
41,247
|
47,700
|
37,695 |
| Financial expenses |
2,507
|
3,635
|
1,506 |
| Earnings before taxes |
2,772
|
-7,964
|
-1,855 |
| EBITDA |
4,047
|
-2,433
|
1,721 |
| Total assets |
50,107
|
47,755
|
55,554 |
| Current assets |
39,405
|
36,336
|
44,773 |
| Current liabilities |
25,832
|
17,892
|
44,686 |
| Equity capital |
3,828
|
-3,678
|
8,673 |
| - share capital |
1,836
|
1,906
|
2,111 |
| Employees (average) |
126
|
128
|
124 |
Financial ratios
| Fiscal year | 2024/04 (consolidated) | 2023/04 (consolidated) | 2021/12 (consolidated) |
| Solvency |
7.6%
|
-7.7%
|
15.6% |
| Turnover per employee |
327
|
373
|
304 |
| Profit as a percentage of turnover |
6.7%
|
-16.7%
|
-4.9% |
| Return on assets (ROA) |
10.5%
|
-9.1%
|
-0.6% |
| Current ratio |
152.5%
|
203.1%
|
100.2% |
| Return on equity (ROE) |
72.4%
|
216.5%
|
-21.4% |
| Change turnover |
-4,707
|
13,654
|
-2,828 |
| Change turnover % |
-10%
|
40%
|
-7% |
| Chg. No. of employees |
-2
|
4
|
-5 |
| Chg. No. of employees % |
-2%
|
3%
|
-4% |
Total value of public sale
| Fiscal year | 2024/04 (consolidated) | 2023/04 (consolidated) | 2021/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.